Top 5 Health Care Stocks That Are Preparing To Pump This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30.

Here’s the latest list of major oversold players in this sector, having an RSI near or below 30.

Esperion Therapeutics, Inc. ESPR

• Esperion announced a $56.7 million registered direct offering with institutional investors. The company’s stock has a 52-week low of $1.26 .
• RSI Value: 22.41
• ESPR Price Action: Shares of Esperion Therapeutics jumped 4.8% to close at $1.76 on Tuesday.

SELLAS Life Sciences Group, Inc. SLS

• SELLAS Life Sciences posted a FY22 loss of $2.13 per share. “Broad success defines the past year, with positive efficacy signals reported across our clinical programs and expansion of our development pipeline,” said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. The company’s stock has a 52-week low of $1.17.
• RSI Value: 28.52
• SLS Price Action: Shares of SELLAS Life Sciences fell 1.3% to close at $1.18 on Tuesday.

Edgewise Therapeutics, Inc. EWTX

• Edgewise Therapeutics posted a Q4 loss of $0.31 per share. "In 2022, we made significant progress advancing our LYNX, CANYON, ARCH and DUNE clinical trials, notably with the 6-month data from the ARCH open label study in individuals with BMD, which reinforces our confidence behind EDG-5506. Moreover, our discovery platform continues to yield differentiated precision medicines, exemplified by EDG-7500, a novel sarcomere modulator for HCM which has entered IND-enabling studies," said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. The company’s stock has a 52-week low of $5.41.
• RSI Value: 29.25
• EWTX Price Action: Shares of Edgewise Therapeutics rose 0.9% to close at $7.00 on Tuesday.

Senseonics Holdings, Inc. SENS

• Senseonics Holdings reported a decline in Q4 earnings. "2022 was a year of notable progress in building the Eversense business, with FDA approval, CE mark and global launch of the E3 system and the acceleration of a pivotal trial for a 365-day sensor configuration that we plan will also support both ICGM and a pediatric indication," said Tim Goodnow, PhD, President and Chief Executive Officer of Senseonics. The company’s 52-week low is $0.69.
• RSI Value: 27.10
• SENS Price Action: Shares of Senseonics Holdings gained 0.1% to close at $0.7112 on Tuesday.

Enovis Corporation ENOV

• Enovis reported mixed Q4 financial results and issued FY23 EPS guidance below estimates. “In our first year as an independent med-tech growth company, Enovis delivered strong financial results,” said Matt Trerotola, Chief Executive Officer of Enovis. The company has a 52-week low of $43.88.
• RSI Value: 29.77
• ENOV Price Action: Shares of Enovis rose 0.2% to close at $50.40 on Tuesday.

Read More: Investor Fear Eases; US Stocks Settle Lower